ARIAD Pharmaceuticals Cancer Drugs Clinical Pipeline Insight

Publish Date:- Nov-2016      No Of Pages (38)

Electronic Access - Single User License $500 Buy Now
CD-ROM Mail Delivery $800Buy Now
Hard Copy Mail Delivery $800 Buy Now
Electronic Access - Multi-User License $1000 Buy Now


“ARAID Pharmaceuticals-Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by ARAID Pharmaceuticals. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “6” cancer drugs in clinical pipeline and majority of them are in preclincal phase. There is 1 cancer drug by ARIAD Pharmaceuticals which is commercially available in the market.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“ARAID Pharmaceuticals - Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.


“ARAID Pharmaceuticals-Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by ARAID Pharmaceuticals. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “6” cancer drugs in clinical pipeline and majority of them are in preclincal phase. There is 1 cancer drug by ARIAD Pharmaceuticals which is commercially available in the market.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“ARAID Pharmaceuticals - Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.

1. ARIAD Pharmaceuticals

  1.1 Business Overview

  1.2 ARIAD Pharmaceuticals Cancer Pipeline Overview

 

2. ARAID Pharmaceuticals Drugs in Preclinical Phase

  2.1 CID Based Cellular Immunotherapies - Bellicum Pharmaceuticals

  2.2 Protein Tyrosine Kinase Inhibitors – ARIAD

 

3. ARAID Pharmaceuticals Drugs in Phase-I

  3.1 Anti-GD2 Chimeric Antigen Receptor T Cell Therapy - Bellicum Pharmaceuticals

 

4. ARAID Pharmaceuticals Drugs in Phase-I/II

  4.1 BPX 501

  4.2 AP 32788

 

5. ARAID Pharmaceuticals Drugs in Preregistration

  5.1 Brigatinib

 

6. Marketed Cancer Drugs by ARAID Pharmaceuticals

  6.1 Ponatinib

 

7. No Development Reported in Cancer Drugs in Clinical Pipeline

  7.1 BPX 201

  7.2 Bone-Targeted mTOR Inhibitors – ARIAD

 

8. Discontinued in Cancer Drugs in Clinical Pipeline

  8.1 Ridaforolimus

  8.2 Ponatinib Companion Diagnostic - ARIAD Pharmaceuticals/MolecularMD

  8.3 BPX 101

  8.4 AP 23451

  8.5 AP 21626


Figure 1 1: ARAID Pharmaceuticals Pipeline by Phase (%)

Figure 1 2: ARAID Pharmaceuticals Pipeline by Phase (Number)

Figure 1 3: ARAID Pharmaceuticals Drugs Discontinued & No Development Reported in Clinical Pipeline by Phase (%)

Figure 1 4: ARAID Pharmaceuticals Drugs Discontinued & No Development Reported in Clinical Pipeline by Phase (Number)